20/20 Biolabs, Inc. (AIDX)
AIDX
Biotech / Pharma
BiotechSign Signal Grade
F
Signal Grade
0.0/100 composite signal score
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Insider Buying
0
Clinical Activity
0
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
0
Clinical Trials
(ClinicalTrials.gov aggregate)
(ClinicalTrials.gov aggregate)
0
PubMed Publications
0
Catalyst Records
ClinicalTrials.gov aggregate as of 2026-10-06. ClinicalTrials.gov
Recent News & SEC Filings
- 20/20 BioLabs to Participate in the Maxim Growth Summit 2026 in New York on October 14, 2026
- 20/20 BioLabs to Host Investor Webinar on October 7, 2026 to Discuss FDA Advisory Committee Vote and New OneTest™ Franchise Model
- 20/20 BioLabs to Host Investor Webinar on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity
- 20/20 BioLabs to Host Investor Webinar on August 5, 2026, to Discuss Commercial Opportunities Following Management’s Recent East Asia Business Development Tour
- 20/20 BioLabs Participates in BIO Asia-Taiwan and Meets with Strategic Counterparties in Taipei, Tokyo, and Seoul to Advance East Asia Roll-Up Strategy
- 20/20 BioLabs Announces Monthly Investor Webinar Series to be Held on the First Wednesday of Each Month
- 20/20 Biolabs' Multi-Cancer Early Detection Blood Test Selected by State of Vermont to Screen up to 4,500 Firefighters
- 20/20 BioLabs Reports First Quarter 2026 Financial Results and Recent Operational Progress
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for 20/20 Biolabs, Inc..
Full AIDX Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.